Assessing congenital malformation risk from medications used in pregnancy: The contribution of NBDPS in pregnancy labeling of prescription drug products

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 103, Issue 8, 2015, Pages 718-720

  Tassinari, Melissa S ^a   Sahin, Leyla ^a   Yao, Lynne P ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

FDA; NBDPS; Pregnancy labeling

Indexed keywords

NARCOTIC ANALGESIC AGENT; PARACETAMOL; PRESCRIPTION DRUG;

ARTICLE; CONGENITAL MALFORMATION; DATA COLLECTION METHOD; DRUG INFORMATION; DRUG LABELING; DRUG SAFETY; FIRST TRIMESTER PREGNANCY; HUMAN; LACTATION; NEURAL TUBE DEFECT; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; SPINAL DYSRAPHISM; STANDARD; TERATOGENICITY; ABNORMALITIES, DRUG-INDUCED; DRUG EFFECTS; FACTUAL DATABASE; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH SURVEY; LEGISLATION AND JURISPRUDENCE; PREGNANCY; PUBLIC HEALTH SERVICE; RISK FACTOR; UNITED STATES;

ABNORMALITIES, DRUG-INDUCED; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); DATABASES, FACTUAL; DRUG LABELING; FEMALE; HUMANS; LACTATION; POPULATION SURVEILLANCE; PREGNANCY; PRESCRIPTION DRUGS; RISK FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84939229658     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.23403     Document Type: Article

References (12)

1. Broussard CS, Rasmussen SA, Reefhuis J, et al. 2011. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol 204:314.e1-e11.
2. FDA Drug Safety Communications. 2015. FDA has reviewed possible risks of pain medicine use during pregnancy. 01/09/2015. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm429117.htm. Accessed March 4, 2015.
3. Federal Register. 2006. Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products. Federal Register 71:3922-3929.
4. Federal Register. 2014. Content and format of labeling for human prescription drug and biological products: requirements for pregnancy and lactation labeling. Fed Regist 79:72064-72103.
5. Feldkamp M, Meyer R, Krikov S, Botto LD. 2010. Acetaminophen use and risk of birth defects. Obstet Gynecol 115:109-115.
6. Holmes L. 2011. Human teratogens: update. 2012. Birth Defects Res A Clin Mol Teratol 91:1-7.
7. Howard TB, Tassinari MS, Feibus KB, Mathis, LL. 2011. Monitoring for teratogenic signals: pregnancy registries and surveillance methods. Am J Med Genet C Semin Med Genet 157:209-214.
8. Rebordosa C, Kogevinas M, Horváth-Puhó E, et al. 2008. Acetaminophen use during pregnancy: effects on risk for congenital abnormalities. Am J Obstet Gynecol 198:178.e1-178.e7.
9. Reefhuis J, Gilboa SM, Anderka M, et al. 2015. The National Birth Defects Prevention Study: a review of the methods. Birth Defects Res Part A Clin Mol Teratol doi: 10.1002/bdra.23384. [Epub ahead of print].
10. Scialli AR. 2014. The National Birth Defects Prevention Study: how to communicate data. Semin Fetal Neonatal Med 19:170e176.
11. Wilson JG. 1973. Evaluation of human teratogenic risk in animals. In: Lee DH, Hewson EW, Okum D, editors. Environment and birth defects. 1st ed. New York: Academic Press. pp. 146-160.
12. Yazdy MM, Mitchell AA, Tinker SC, et al. 2013. Periconceptional use of opioids and the risk of neural tube defects. Obstet Gynecol 122:838-844.